Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
Annals of the Rheumatic Diseases|March 30, 2011
Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritisSaskia Vosslamber, Hennie G Raterman, Tineke C T M van der Pouw Kraan, et al.
Expert Opinion on Drug Safety|February 16, 2023
Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseasesHelen R Gosselt, Jette A van Lint, Leanne J Kosse, et al.
Arthritis and Rheumatism|October 31, 2009
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective studyMike J L Peters, Vokko P van Halm, Alexandre E Voskuyl, et al.
Clinical and Experimental Rheumatology|September 10, 2019
The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisationLea C Berkhout, Erik H Vogelzang, Margreet M Hart, et al.
Rheumatology (Oxford, England)|October 7, 2022
Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trialLinda Hartman, Linda A Rasch, Samina A Turk, et al.
RMD Open|June 6, 2025
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trialKristina Lend, Jos Wr Twisk, Nupur Kumar, et al.
Annals of the Rheumatic Diseases|May 3, 2025
Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trialMaike H M Wientjes, Sadaf Atiqi, Gerrit J Wolbink, et al.
The Journal of Rheumatology|May 17, 2019
Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal StudyRabia Agca, Luuk H G A Hopman, Koen J C Laan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2020
Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled TrialTamara Rusman, Mignon A C van der Weijden, Michael T Nurmohamed, et al.
Drug Safety|May 27, 2020
Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory DiseasesJette A van Lint, Naomi T Jessurun, Renske C F Hebing, et al.
Pageof 18